SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...

Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning. The round was led by ...